araag2/HINT huggingface dataset:
Clinical trial NCT00617253 (phase 2, status: completed)
Conditions: cancer, renal cell carcinoma
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: recombinant interleukin-21, sunitinib, recombinant interleukin-21, recombinant interleukin-21, recombinant interleukin-21
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically verified and surgically incurable stage IV Renal Cell Carcinoma

          -  ECOG performance status of 0 or 1 (i.e. good performance status)

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Prior systemic therapy for metastatic disease

          -  Radiotherapy within the last 4 weeks prior to start of treatment

          -  Receipt of any investigational drug within 3 months of starting treatment

          -  History of any other active malignancy within five years prior to enrolment
Clinical trial NCT01643408 (phase 2, status: completed)
Conditions: acute lymphoblastic leukemia, lymphoblastic lymphoma
ICD codes: C91.01, C91.02, C91.00, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: asparaginase erwinia chrysanthemi
SMILES: N[C@@H](CC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma,

          -  Ages >/= 1 and </= to 30 years at the time of initial diagnosis

          -  Undergoing asparaginase treatment for ALL or lymphoblastic lymphoma

          -  Documented Grade 2 or higher hypersensitivity reaction to native or pegylated E. coli
             asparaginase or Calaspargase pegol

          -  Must have two remaining weeks of native E. coli asparaginase treatment or 1 remaining
             dose of either Pegaspargase or Calaspargase pegol

          -  Direct bilirubin less than or equal to Grade 2

          -  Amylase and lipase within normal limits (per institutional standards)

          -  signed informed consent byt he patient is greater than or equal to 18 years or by the
             parent if the patient is younger than 18 years old.

        Exclusion Criteria:

        -
Clinical trial NCT01710046 (phase 2, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: (cp-6890,550) tofacitinib, placebo, (cp-690,550) tofacitinib, placebo
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults over 18 years of age with a diagnosis of chronic moderate to severe plaque
             psoriasis for at least 12 months; in generally good health; on stable dose of
             non-prohibited medications; able to stop current psoriasis therapy (systemic or
             topical) for several weeks prior to and during study participation.

        Exclusion Criteria:

          -  Serious underlying disease including viral disorders such as hepatitis or HIV or skin
             condition that would interfere with skin biopsies or evaluation of psoriasis;
             conditions that could interfere with drug absorption after oral administration;
             history of malignancy or auto-immune disease.

          -  Use of oral or injected corticosteroids (steroids).
Clinical trial NCT01163721 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ranolazine, placebo
SMILES: COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant with T2DM on stable non-insulin antidiabetic therapy in addition to diet
             and exercise

          -  Body mass index (BMI) ≥ 25 kg/m^2 and ≤ 40 kg/m^2

          -  HbA1c 7 - 11%

          -  Ability and willingness to maintain a complete and accurate Subject Activity Log
             during the course of the trial

          -  Female of child-bearing potential must have agreed to use effective methods of
             contraception

          -  Ability to understand and willing to sign written informed consent

        Exclusion Criteria:

          -  Type 1 Diabetes Mellitus (T1DM)

          -  T2DM with history of or current insulin therapy. Prior use during pregnancy or
             gestational diabetes was acceptable.

          -  History of ketoacidosis or ketosis-prone diabetes

          -  Clinically significant complications of diabetes that in the judgment of the
             investigator would have made participant unsuitable to participate in this trial

          -  History of a severe episode of hypoglycemia

          -  Change in non-insulin antidiabetic therapy in addition to diet and exercise < 2 months
             prior to screening

          -  Any clinically significant cardiovascular event < 2 months prior to screening

          -  Clinically significant, inadequately controlled or unstable hypertension

          -  Hospitalization < 2 months prior to screening

          -  Major surgery < 3 months prior to screening

          -  Weight loss medication (prescription or non-prescription) < 2 months prior to
             screening
Clinical trial NCT00243711 (phase 2/phase 3, status: completed)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: carboxymethylcellulose sodium and glycerin
SMILES: OCC(O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Mild, Moderate, or Severe Dry Eye Symptoms and current eye drop use;

          -  Reduced tear stability or tear production

        Exclusion Criteria:

          -  NONE
Clinical trial NCT00298194 (phase 2, status: completed)
Conditions: dyspepsia
ICD codes: K30
Drugs: z-338
SMILES: COC1=C(OC)C=C(C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C)C(O)=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects with functional dyspepsia Positive documented diagnosis of FD via RomeII
             criteria and three or more moderate symptoms of Gastrointestinal Score

          2. Subjects with no history of functional dyspepsia Clinical assessment, physical
             examination and laboratory testing without evidence for relevant abnormality.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00559455 (phase 2, status: completed)
Conditions: carcinoma, hepatocellular
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: oxaliplatin, fluorouracil, leucovorin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Lists of Inclusion and Exclusion criteria:

          -  Patients must have histologically confirmed hepatocellular carcinoma

          -  Patients must have measurable disease by CT scan

          -  Have not received previous palliative systemic chemotherapy for metastatic disease.
             (Adjuvant chemotherapy or radiation therapy for non target lesion can be allowed.)

          -  Patients progress after previous local treatment and at the time of randomization is
             at least 4 weeks after the last interventional therapy (Hepatic Artery Infusion,
             Trans-Artery Embolization or Trans-Artery Chemo-Embolization) or at least 4 weeks
             after the last radiotherapy/ablation/ Percutaneous Ethanol Injection to the target
             lesion.

          -  WHO 0-2 grades (Karnofsky Performance Score ≥ 70)

          -  Patients must have adequate organ and marrow function:

               -  Neutrophilus ≥ 1.5 x 10^9/L

               -  Platelets ≥ 75 x 10^9/L

               -  Asparagine AminoTransferase, Alanine AminoTransferase < 2.5 x Upper Normal
                  Limit(UNL)

               -  Total Bilirubin ≤ 1.5 x UNL

               -  International Normalized Ratio < 1.5

               -  Child stage A or B

               -  Creatinine ≤ 1.5 X UNL

        Exclusion Criteria:

          -  Documented allergy to platinum compound or to other study drugs.

          -  Active Gastro-Intestinal bleeding and active haematologic malignancy

          -  Previous liver transplantation.

          -  Patients concomitantly receiving any other anti-cancer therapy.

          -  Patients who are receiving any other study treatments.

          -  Pregnant or lactating women or women of childbearing potential without proper
             contraceptive methods.

          -  History of other malignant diseases, except cured basal cell carcinoma of skin and
             cured carcinoma in-situ of uterine cervix.

          -  Central nervous system metastasis

          -  Other serious illness or medical conditions

          -  Neuropathy ≥ grade 2

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01327183 (phase 2, status: completed)
Conditions: myocardial infarction
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: ro4905417, ro4905417, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, >18 to <75 years of age

          -  Non ST-elevation myocardial infarction

          -  Woman of childbearing potential will be allowed only if using two acceptable methods
             of contraception

          -  Body mass index (BMI) </= 40 kg/m2

        Exclusion Criteria:

          -  Acute ST-elevation myocardial infarction (STEMI)

          -  Culprit coronary lesion with a total thrombotic occlusion or a lesion requiring the
             use of distal embolization protection or thrombectomy devices

          -  Percutaneous coronary intervention (PCI) within the past 72 hours

          -  Thrombolytic therapy within the past 7 days

          -  Major surgery within the past 3 months

          -  History of cerebral vascular disease or stroke in the past 3 months

          -  Bleeding disorders

          -  Inadequately controlled severe hypertension

          -  Prior coronary artery bypass graft (CABG) surgery

          -  Decompensated heart failure (oedema and/or rale)

          -  Acute infection at screening or active chronic infection within 3 months prior to PCI

          -  Patients known to be HIV positive, patients receiving antiretroviral drugs, or
             immuno-suppressed patients

          -  Uncontrolled diabetes mellitus (HbA1C >10%) at baseline
Clinical trial NCT01091870 (phase 2, status: withdrawn)
Conditions: subarachnoid hemorrhage, cerebral vasospasm, rupture of intracranial aneurysm
ICD codes: I60.8, I60.9, I69.020, I69.021, I69.022, I69.090, I69.091
Drugs: placebo, sildenafil citrate, 25 mg, 3 times a day., sildenafil citrate 50 mg, 3 times a day
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1, CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
Reason stopped: 
    absence of inclusion criteria
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females between 20 and 80 years old

          -  Subarachnoid hemorrhage confirmed by CT with Fisher III or IV criteria (blood in
             cisterns larger than 1 mm with or without blood in the ventricular system).

          -  Aneurysm detected in the conventional angiography, or angio-CT or angio - MRI.

          -  Patient underwent surgery for clipping or endovascular treatment in the first 72 hours
             after the ictus.

          -  Consent form signed by the patient or legal responsible.

        Exclusion Criteria:

          -  Patient (or legal responsible) refuses to participate.

          -  Impossibility to collect consent form.

          -  Hemodynamical instability.

          -  Previous cardiac ischemic disease.

          -  History of cardiac arrhythmia within the last 6 months.

          -  History of Retinitis Pigmentosa.

          -  Previous use of drugs witch can interact with sildenafil (specially nitrates).

          -  Pregnancy.

          -  Known hypersensibility to Sildenafil.
Clinical trial NCT00245011 (phase 2, status: completed)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: ifosfamide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion

          -  Diagnosis of osteosarcoma

               -  High-risk disease, meeting 1 of the following criteria:

                    -  Recurrent disease

                    -  Refractory to conventional therapy

                    -  Newly diagnosed metastatic disease with ≥ 4 pulmonary nodules or multiple
                       bone lesions

                    -  Unresectable primary tumor

               -  Prior intralesional resection allowed

          -  Measurable disease by technetium Tc 99m diphosphonate bone scan

          -  Refractory to all standard therapies or highly unlikely to respond to conventional
             treatment

          -  Performance status Karnofsky 60-100%

          -  Life expectancy more than 8 weeks

          -  Absolute neutrophil count > 500/mm^3

          -  Platelet count > 50,000/mm^3

          -  Creatinine clearance > 70 mL/min OR * Radioisotope glomerular filtration rate normal

          -  Recovered from prior chemotherapy

        Exclusion

          -  Pregnant or nursing

          -  Positive pregnancy test for females of childbearing potential

          -  Fertile patients do not agree to use effective contraception

          -  Prior radiotherapy to the site of currently active disease

          -  Concurrent enrollment on protocol JHOC-J0094 allowed
Clinical trial NCT00718718 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cnto 136 100 mg, cnto 136 50 mg, cnto 136 25 mg, placebo, methotrexate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with rheumatoid arthritis (RA) for at least 4 months prior to screening

          -  Have been treated and having an inadequate response with the tolerated dose of
             methotrexate (MTX) (at least 15mg/week) for at least 4 months prior to screening. MTX
             doses of 10 or 12.5 mg/week are allowed if participant had intolerance of 15 mg/week

          -  MTX route of administration and dose (not to exceed 25 mg/week) should be stable for
             at least 6 weeks prior to the start of the study medication

          -  Have active RA as defined by persistent disease activity with at least 6 swollen and 6
             tender joints, at the time of screening and baseline, and either anti-cyclic
             citrullinated peptide antibody-positive or rheumatoid factor positive at screening

          -  C-reactive protein greater than or equal to 1.0 mg/dL (10 mg/L)

          -  Agree to use one of the contraception methods defined in the protocol

        Exclusion Criteria:

          -  Have inflammatory diseases other than RA that might confound the evaluation of the
             benefit of CNTO 136 therapy in arthritis

          -  Family history of/ have long QT syndrome; or a history of second or third-degree heart
             block

          -  Received systemic immunosuppressives or disease modifying antirheumatic drug other
             than MTX, sulfasalazine, hydroxychloroquine or chloroquine within 4 weeks prior to the
             start of study medication

          -  Received intra articular (into joints), intramuscular, or intravenous corticosteroids
             within 4 weeks prior to the start of study medication

          -  Positive human immunodeficiency virus test, hepatitis B or hepatitis C

          -  History of / have chronic or recurrent infectious disease, history of / active
             tuberculosis

          -  Have serious infection within 2 months prior to start of study medication
Clinical trial NCT00677079 (phase 2, status: completed)
Conditions: primary peritoneal cancer, advanced epithelial ovarian cancer
ICD codes: K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: iniparib
SMILES: NC(=O)C1=CC(=C(I)C=C1)[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female, age 18 or older;

          -  Histologically or cytologically confirmed advanced epithelial ovarian cancer,
             fallopian tube cancer or primary peritoneal cancer (stage III or IV);

          -  At least one previous regimen with platinum/taxane combination therapy and no curative
             options as determined by their physician (no limit on the number of prior therapies);

          -  Confirmed BRCA1 or BRCA2 status;

          -  One or more measurable lesions, at least 10mm in longest diameter by spiral computed
             tomography (CT) scan or 20mm in longest diameter when measured with conventional
             techniques (palpation, plain x-ray, CT or magnetic resonance imaging (MRI));

          -  Karnofsky performance status ≥70%;

          -  Estimated life expectancy of at least 16 weeks.

        Exclusion Criteria:

          -  Normal clinical laboratory values;

          -  Any anti-cancer therapy within 21 days prior to study start;

          -  Any other malignancy within 3 years of study start, except adequately treated
             carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of the breast, or
             basal or squamous cell skin cancer;

          -  Active viral infection including HIV/AIDS, Hepatitis B or Hepatitis C infection;

          -  Active central nervous system or brain metastases;

          -  History of seizures or current treatment with anti-epileptic medication;

          -  Persistent grade 2 or greater toxicities from prior therapy, excluding alopecia.
Clinical trial NCT00528528 (phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: telaprevir, peg-ifn-alfa-2a, peg-ifn-alfa-2b, ribavirin (rbv) tablet, ribavirin (rbv) capsule
SMILES: [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic genotype 1 Hepatitis (inflammation of the liver) C infection

          -  Never been treated for Hepatitis C Viral (HCV) infection

          -  No clinically significant lab abnormalities

          -  Amount of HCV Ribonucleic acid (RNA) in the blood more than 10,000 international
             units/milliliter (IU/mL) at entry

          -  Liver biopsy or "Fibroscan" test performed during screening or in the past 3 years

        Exclusion Criteria:

          -  Contra-indications for starting anti-HCV therapy

          -  History or evidence of liver cirrhosis (serious liver disorder in which connective
             tissue replaces normal liver tissue, and liver failure often occurs) or decompensated
             liver disease

          -  Any evidence of significant liver disease in addition to Hepatitis C

          -  Infected with Human Immunodeficiency Virus (a life-threatening infection which you can
             get from an infected person's blood or from having sex with an infected person) or
             Hepatitis B

          -  Women who are pregnant (carrying an unborn baby), planning to be pregnant or
             breastfeeding or the partner of a woman who is pregnant or breastfeeding
Clinical trial NCT01306617 (phase 2, status: completed)
Conditions: chronic hepatitis c infection, hepatitis c, hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2, B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-450, abt-333, ribavirin, ritonavir
SMILES: [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic hepatitis C virus (HCV)

          -  Treatment naive, null or partial responders to previous treatment with peginterferon
             and ribavirin

          -  Males and females 18-65 years old

          -  Body mass index 18 to < 35 kg/m^2

          -  Females must be postmenopausal for at least 2 years or surgically sterile

        Exclusion Criteria:

          -  Cirrhosis or extensive bridging fibrosis

          -  History of cardiac disease

          -  Positive screen for certain drugs or alcohol

          -  Abnormal laboratory results

          -  Significant sensitivity to any drug

          -  Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody

          -  Use of strong cytochrome P450 3A (CYP3A), cytochrome P450 2C8 (CYP2C8), and organic
             anion transporting polypeptide 1B1 (OATP1B1) enzyme inducers or inhibitors within 1
             month of dosing
Clinical trial NCT01215565 (phase 2, status: terminated)
Conditions: hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sutent
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Reason stopped: 
    lack of inclusion
  
Eligibility criteria:

        Inclusion Criteria:

          -  Fibrolamellar hepatocellular carcinoma histopathologically proven

          -  Inoperable/advanced (Tumor recurrence inoperable or metastatic with no surgical
             indication).

          -  Available Tumor tissue for analysis(biopsy or surgical specimen)

          -  Performance status WHO ≤ 2.

          -  Adequate organ function :

               -  Hematology (absolute neutrophil count equal or superior to 1,5 x 10*9/l ,
                  platelet equal or superior to 100 x 10*9/l),

               -  clearance of creatinine > 60 ml/min),

               -  AST/ALT ≤ 5 N, PAL ≤ 5 N, total bilirubin ≤ 2N.

        Exclusion Criteria:

          -  Hypersensitivity to sunitinib.

          -  Contraindication to sunitinib, including uncontrolled hypertension, medical history of
             cerebrovascular accident, unstable cardiac pathology despite optimal medical therapy
             (myocardial infarction within the 6 months prior to study drug administration,
             severe/unstable angina ), active hemorrhagic syndrome or concomitant treatment with
             anticoagulants.

          -  Any severe acute or chronic co-morbid that may compromise to comply with study
             participation : uncontrolled infection, symptomatic congestive heart failure, liver
             disturbance, chronic renal failure, active gastro-duodenal ulcer (nonexhaustive list)

          -  Known brain metastases.

          -  Diagnosis of any second malignancy within the last 3 years, except for basal cell or
             squamous cell skin cancer, or in situ carcinoma of the cervix uteri

          -  Current treatment on another clinical trial.

          -  Prior treatment with an investigational agent within 4 weeks

          -  Patient on i.v bisphosphonate therapy